| Literature DB >> 26389929 |
Junyan Teng1,2, Yanping Wei3, Fengming Su4, Zhiping Guo2, Jing-Quan Zhong5.
Abstract
In this study, a multiple linear regression model to evaluate the risk of morbidity and mortality of ischemic cardiovascular disease is demonstrated. In this model, predictor variables are selected from physiological chemicals in a blood test of the subjects. Meanwhile, the calculated risk score is selected as a response variable. Four major latent variables including hepatic, nephric, metabolic, and BMI (Body Mass Index) are revealed by performing statistical and principal component analysis for the collected survey data. The analyzed result also shows that the cardiac disorder is correlated with symptoms of abnormal BMI, hepatic disorder, nephric disorder, and metabolic disorder. Thus, the risk of morbidity and mortality of ischemic cardiovascular disease can be assessed from the proposed multiple regression model.Entities:
Keywords: cardiac disorder; hepatic disorder; morbidity and mortality; physiological chemicals; risk score
Mesh:
Substances:
Year: 2015 PMID: 26389929 PMCID: PMC4586690 DOI: 10.3390/ijerph120911549
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Pearson’s Correlation Coefficients between risk scores (RS) and the markers. Significance test p < 0.001 is required to reject Null hypothesis. Null hypothesis means the linear correlation is not existed at the significance p-value that p > 0.001.
| BMI | HDL | LDL | TG | CK | UA | ALP | ALT | GOT | GGT | |
|---|---|---|---|---|---|---|---|---|---|---|
| A ** | 0.481 | (0.111) * | 0.300 | 0.292 | 0.241 | 0.220 | 0.187 | 0.191 | 0.127 | 0.286 |
| B ** | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| C ** | 0.177 | 0.033 | 0.038 | 0.110 | 0.074 | (0.140) * | 0.145 | 0.125 | 0.138 | 0.253 |
| D ** | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| E ** | 0.385 | 0.040 | 0.192 | 0.224 | −0.011 | 0.071 | 0.099 | 0.085 | 0.058 | 0.237 |
| F ** | 0.000 | 0.063 | 0.000 | 0.000 | 0.334 | 0.004 | 0.000 | 0.001 | 0.013 | 0.000 |
* Negative Numbers; ** A: all RS selected (include both male and female); B: p-value for significance (one-tailed) test of A; C: data selected only at RS = 3 (include both male and female); D: p-value for significance (one-tailed) test of C; E: all RS selected for male subjects only; F: p-value for significance (one-tailed) test of E.
Abnormal level of the selected markers in blood.
| Markers | Level |
|---|---|
| BMI | 25 |
| HDL/high density lipoprotein | >1.8 mmol/L |
| LDL/low density lipoprotein | >3.36 mmol/L |
| TG/triglyceride | >2.25 mmole/L |
| CK/creatininekinase | male > 104 μmol/L |
| female > 84 μmol/L | |
| Uric Acid | male > 416 μmol/L |
| female > 257 μmol/L | |
| ALP/alkaline phosphatase | >129 U/L |
| GOT/oxaloacetic transaminase | >33 U/L |
| GGT/glutamyltranspeptidase | >40 U/L |
| ALT/alanine Aminotransferase | >81 U/L |
RM1 multiple-variable regression model of the selected markers in blood for the clinical population collected in Henan Province, China.
| RM1: RS | Coefficients without Standardization | Standardized Coefficient | Significance | 95.0% Confidence Interval of β | |||
|---|---|---|---|---|---|---|---|
| Estimation of β | Standard Error | Beta Distribution | Lower Bound | Upper Bound | |||
| Constant | −12.714 | 0.749 | −16.973 | 0.000 | −14.183 | −11.245 | |
| BMI | 0.409 | 0.022 | 0.389 | 18.980 | 0.000 | 0.366 | 0.451 |
| HDL | 0.585 | 0.232 | 0.049 | 2.519 | 0.012 | 0.130 | 1.041 |
| LDL | 0.801 | 0.086 | 0.173 | 9.310 | 0.000 | 0.632 | 0.970 |
| TG | 0.227 | 0.044 | 0.100 | 5.134 | 0.000 | 0.140 | 0.314 |
| CK | 0.020 | 0.005 | 0.082 | 4.184 | 0.000 | 0.011 | 0.030 |
| UA | 0.248 | 0.055 | 0.085 | 4.488 | 0.000 | 0.140 | 0.356 |
| ALP | 0.011 | 0.003 | 0.070 | 3.717 | 0.000 | 0.005 | 0.016 |
| ALT | −0.014 | 0.006 | −0.081 | −2.429 | 0.015 | −0.025 | −0.003 |
| GOT | 0.013 | 0.011 | 0.039 | 1.215 | 0.225 | −0.008 | 0.034 |
| GGT | 0.011 | 0.002 | 0.113 | 5.317 | 0.000 | 0.007 | 0.015 |
Impact weighting coefficients of the principal components presented by the selected physiological chemicals (markers) in blood for a specific RS value.
| H | B | N | M | |
|---|---|---|---|---|
| BMI | 0.182 | 0.744 | −0.009 | −0.003 |
| HDL | 0.494 | −0.196 | −0.158 | −0.302 |
| LDL | 0.329 | 0.482 | 0.141 | −0.520 |
| TG | 0.227 | 0.544 | −0.168 | 0.221 |
| CK | −0.216 | 0.116 | 0.737 | 0.358 |
| UA | −0.289 | 0.369 | 0.598 | −0.224 |
| ALP | 0.193 | 0.480 | −0.277 | −0.143 |
| ALT | 0.746 | −0.109 | 0.475 | 0.017 |
| GOT | 0.808 | −0.325 | 0.343 | −0.089 |
| GGT | 0.750 | −0.031 | −0.198 | 0.176 |
RM2 multiple regression model coefficients of the principal components of the correlation matrix of the selected physiological chemicals in the blood of subjects.
| RM2: RS | Coefficients without Standardization | Standardized Coefficient | Significance | 95.0% Confidence Interval of β | |||
|---|---|---|---|---|---|---|---|
| Estimation of β | Standard Error | Beta Distribution | Lower Bound | Upper Bound | |||
| Constant | 11.417 | 0.062 | -- | 185.305 | 0.000 | 11.296 | 11.538 |
| Hepatic | 0.222 | 0.041 | 0.042 | 5.398 | 0.000 | 0.141 | 0.303 |
| BMI | 0.425 | 0.030 | 0.123 | 14.168 | 0.000 | 0.366 | 0.484 |
| Nephric | −0.101 | 0.029 | −0.031 | −3.494 | 0.000 | −0.157 | −0.044 |
| Metabolic | 1.914 | 0.020 | 0.886 | 96.382 | 0.000 | 1.875 | 1.953 |
Coefficients of determination (CD).
| R | R Square (CD) | Standard Error of the Estimation | Durbin-Watson Test | |
|---|---|---|---|---|
| RM1 | 0.580 | 0.336 | 2.726 | 1.359 |
| RM2 | 0.937 | 0.878 | 1.169 | 1.764 |